ABSTRACT
INTRODUCTION
Vascular access is always a challenge for oncology patients who require frequent blood sampling and administration of antineoplastic agents, antibiotics, intravenous fluids, nutritional support, and blood products. 1, 2 Nonetheless, the upper extremity veins are rapidly exhausted by repeated venipuncture as well as administration of irritating antibiotics and chemotherapy. An indwelling central venous catheter (CVC) facilitates the supportive care of oncology patients, 1,2 but also carries different risks and complications. 3, 4 Several types of indwelling CVCs are commonly inserted in oncology patients, namely (a) tunnelled CVC, including Hickman catheter, [5] [6] [7] [8] [9] (b) peripherally inserted central venous catheter (PICC), 10 (c) temporary non-tunnelled CVC, 9 and (d) subcutaneous totally implantable intravascular devices, e.g. Port-A-Cath (Smiths Industries Medical Systems, Deltec, Inc., St. Paul [MN] , USA), MediPort (Norfolk, Medina [NY], USA). 11, 12 Our study focused on the Hickman catheter and PICC that are more widely used in our hospital.
Both the Hickman catheter and PICC provide effective vascular access, but are associated with risks and complications. The most common complication is infection. From a large review article in 2005 of 200 prospective studies over 40 years, 4 the catheter-related bloodstream infection (CRBSI) rate per 1000-catheterdays of cuffed and tunnelled CVC was 1.6 and that for PICC was 1.1 (2.1 for inpatient and 1.1 for both inpatient and outpatient). In addition to infection, other non-infectious complications occur. 2, 13 During percutaneous catheterisation there may be arterial puncture, haematoma, pneumothorax and haemothorax, as well as mechanical problems that can cause catheter malfunction, including migration, thrombosis, embolisation, cuff erosion, and leakage.
Reports about CRBSI rates of Hickman catheters and PICCs revealed diverse results. 4, [14] [15] [16] [17] [18] [19] [20] [21] The 2011 Guidelines for the Prevention of Intravascular CatheterRelated Infections by Centers for Disease Control and Prevention, USA, 22 offered no recommendation on the selection of Hickman catheter or PICC but suggested that it should be based on the intended purpose and duration of use, known infectious and non-infectious complications, and experience of individual catheter operators.
There is currently no standard protocol in our hospital with regard to selection of catheter in oncology patients. The objective of our study was thus to compare the incidence of CRBSI and non-infectious complication rate for both Hickman catheter and PICC in oncology patients.
METHODS
During the period January 2008 to December 2013, oncology patients who underwent Hickman catheter or PICC placement at the radiology department of a regional hospital in Hong Kong were retrospectively reviewed.
The Hickman catheter used was Hickman® 9.0 French Dual Lumen Catheter and the PICC was PowerPICC® 5.0 French Single Lumen Catheter. Both models were obtained from Bard Access Systems. An aseptic and Seldinger technique was used for insertion under ultrasound guidance, using the Philips iU22 xMATRIX Ultrasound System together with Probe L12-5 50 mm Linear Array. The catheter tip was placed in the lower part of the superior vena cava, and its position confirmed with fluoroscopy.
All oncology patients followed the standard postHickman catheter and PICC care guidelines prepared Hospital records, radiological and microbiological reports, and medical notes from electronic Patient Record were gathered and analysed. Other data collected included the following: patient gender, age, type of malignancy, type of catheter, site of catheter insertion, indication and date of catheter insertion and removal, the presence of CRBSI, the presence of noninfectious complication(s), and the presence of catheter tip culture and peripheral blood culture.
CRBSI was defined as (i) positive catheter tip culture, (ii) positive blood culture from the catheter, or (iii) septicaemia that resolved only after catheter removal. 13 Total catheter days was defined as the time interval between catheter insertion and catheter removal. The time to infection onset was defined as the interval between catheter insertion and the date when the CRBSI criteria were fulfilled. CRBSI rate per 1000-catheterdays was defined as total number of infections divided by the total catheter days times 1000. 
RESULTS

Descriptive Results
From January 2008 to December 2013, there were 498 cases of Hickman catheter and PICC insertion, of whom 190 cases were oncology patients and were analysed. Patients' age ranged from 9 to 92 years (mean 47.0, median 49.0 years). Demographic data of both groups are summarised in Table 1 . Of the 190 cases, 161 were Hickman catheters and 29 were PICC. Reasons for catheter insertion were chemotherapy (n = 163), total parenteral nutrition (n = 18), and vascular access (n = 9).
For number of catheter insertions per patient, 124 patients in the Hickman group had one catheter insertion only, and 11 patients had multiple catheter insertions. In the PICC group, three patients had multiple catheter insertions. In addition, there were seven patients with multiple catheter insertions with a combination of Hickman and PICC catheters ( Table 2) .
Demographics
Hickman catheter (n = 161) PICC (n = 29) Total (n = 190) Abbreviations: PICC = peripherally inserted central venous catheter; TPN = total parenteral nutrition.
Type of malignancy was also analysed: 110 cases were haematological (71 leukaemia, 29 lymphoma) and 80 were non-haematological (most were upper and lower gastrointestinal, breast, lung, and head and neck malignancies) [ Table 3 ].
For site of insertion, among the 161 Hickman catheters, most were inserted into the right jugular vein (n = 134).
In the 29 PICC group, most were inserted into the right basilic vein (n = 17) or right cephalic vein (n = 5) [ Table  4 ].
Analytical Results
The total catheter days of the Hickman and PICC groups was 28,365 days and 2419 days, respectively. The mean catheter days was 176 days (range, 0-869 days) for the Hickman group and 83 days (range, 3-419 days) for the PICC group (p < 0.001) [ Table 5 ].
Overall, 38 of 161 cases in the Hickman group and 4 of 29 cases in the PICC group had CRBSI (p = 0.241). The time to infection onset was 149.9 days for the Hickman group and 55.3 days for the PICC group (p = 0.187). The CRBSI rate per 1000-catheter-days was 1.340 for the Hickman group, 1.654 for the PICC group, and 1.364 for overall. For non-infectious complications, 15 Hickman patients and six PICC patients had complications. Details are shown in Table 5 .
There was no statistically significant difference between the two groups in terms of number of CRBSIs (p = 0.241), time to infection onset (p = 0.187), noninfectious complication rate (p = 0.101), and overall complication rate (p = 0.766).
S u b g r o u p a n a l y s i s w a s p e r f o r m e d i n t h e 1 1 0 haematological and 80 non-haematological cases.
For the haematological group, there were 30 cases of CRBSI in the Hickman group but none in the six PICC cases. There was no statistically significant difference in terms of number of CRBSIs (p = 0.186), non-infectious complication rate (p = 0.072), and overall complication rate (p = 1.000) [ Table 6 ]. In the non-haematological group, the CRBSI rate per 1000-catheter-days in the PICC group was higher than that in the Hickman group, but there was no statistical significant difference in Table 5 . Catheter days and complication rates. Table 6 . Catheter days and CRBSI (haematological malignancy subgroup). Table 7 . Catheter days and CRBSI (non-haematological malignancy subgroup). introduced in 1973. The wider luminal diameter of 1.6 mm in Hickman catheter compared with 1.0 mm of the Broviac catheter allowed easier venous blood sampling and infusion. 6, 7 The Dacron cuff serves as a barrier to infection by allowing fibrous ingrowth.
The PICC was first introduced by Hoshal in 1975. 23 It is a silicone-elastomer catheter that is inserted into the basilic or cephalic vein, and was first used for total intravenous nutrition. It gained popularity in the 1990s and is now used for chemotherapy, vascular access, blood product transfusion, venous sampling, and nutritional support.
Both Hickman catheter and PICC have been in use for more than 40 years, with a diversity in the reports about infection rates. 4, [14] [15] [16] [17] [18] [19] [20] [21] Some studies have suggested a lower risk of infection in PICC, [14] [15] [16] [17] [18] [19] but others disagree. 4, 20, 21 In the systematic review by Maki in 2006, 4 PICC in hospitalised patients showed the highest CRBSI rate (2.1 per 1000-catheter-days; 95% confidence interval [CI], 1.0-3.2), followed by cuffed and tunnelled CVC (1.6 per 1000-catheter-days; 95% CI, 1.5-1.7), then pooled mean of inpatient and outpatient PICC (1.1 per 1000-catheterdays; 95% CI, 0.9-1.3), and outpatient PICC (1.0 per 1000-catheter-days; 95% CI, 0.8-1.2).
In another prospective cohort study of all adult patients with a CVC in a haematology-oncology unit from January 2004 to March 2007, 14 among the 1127 CVCs (154 Hickman catheters, 807 PICC, 166 non-tunnelled catheters or implantable devices) in 727 patients, the hazard ratio of CRBSI for the Hickman catheter was 2.78 times that for PICC (p = 0.0035).
A most recent systematic review and meta-analysis in 2013 by Chopra et al 16 compared the infection rate of PICC and CVC. He included studies that involved patients aged 18 years or above with PICC or CVC insertion, and reported the infection rates. The pooled meta-analyses of the 23 studies (52,175 cases) showed a lower infection risk for PICC than CVC, with a relative risk (RR) of 0.62 when number of infection cases was compared. Of the 13 studies (50,667 cases) that reported infection in catheter-days, the RR of PICC to CVC was 0.92 only (range, 0.41-1.27). When only inpatients were compared, there was no statistically significant difference in risk of infection between PICC and CVC (RR, 0.72; range, 0.41-1.27). This difference may be attributed to various factors. 4 First of all, the study population possibly involved a quite heterogeneous group of patients from infants to adults, from intensive care patients to oncology patients or haemodialysis patients. They might also have had a range of immunity status or underlying disease. Second, the catheter might have been inserted for different purposes and durations. Removal of catheter could have been for treatment completion, or due to infection, complication, or patient death. Third, the definition of CRBSI varied in different studies. 2, 4, 16, 22 Routine catheter removal in suspected cases of infection was not suggested, 1, 2, 22, 24, 25 making the semi-quantitative and quantitative diagnosis difficult. In addition, it remained undetermined whether CVC change over a guidewire, insertion of a new CVC at a new site, or watchful waiting was preferred among patients with suspected but unconfirmed catheter-related infection, pending blood culture results. 25 There was no statistically significant difference between Hickman catheter and PICC in terms of CRBSI (number of infection and time to infection onset), non-infectious complications, or overall complications.
The CRBSI rate in our study was comparable with other studies. The CRBSI rate for the Hickman group and PICC group was 1.340 and 1.654 per 1000-catheterdays respectively, comparable with the Maki systematic review 4 that reported 1.6 for Hickman catheter (range, 1.5-1.7) and 2.1 for PICC inpatients (range, 1.0-3.2).
Number of catheter days in our study was diverse, ranging from 0 to 869 days (Figure) . Catheter days in the Hickman group were significantly longer than those in the PICC group. This may be because clinicians tend to use Hickman lines in patients who require a longer duration of therapy, reserving PICC for those who require shorter treatment duration. Cases with CVC insertion for more than 1 year were analysed. Of the 22 cases, 21 were Hickman catheters and only one was PICC.
Cases with short duration of catheter use were analysed as outlier cases. We used two cut-offs at 10 days and 30 days arbitrarily. For the 13 cases with CVC inserted for ≤10 days, eight were Hickman catheters and five were PICC; six were removed as the patient died, one was due to treatment completion, three were due to infection, and three were due to non-infectious complications. When the 30-day mark was used, 35 cases (23 Hickman catheters and 12 PICC) had the catheter in situ for <30 days; 13 were removed because the patient died, eight were due to treatment completion, one was pulled out by the patient, and 11 were due to complications. A considerable number of catheters were removed shortly after insertion because of patient demise.
The short-catheter-days outliers may affect the statistical comparison between Hickman and PICC groups. Therefore, we also analysed the CRBSI of two groups when the outliers were excluded. When the catheterdays of ≤10 days as well as ≤30 days were excluded, the number of CRBSI cases, mean time to infection onset, non-infectious complication rate, and overall complication rate showed no statistically significant difference between Hickman and PICC groups. This was consistent with our overall findings.
Despite the wide range of catheter days, it should be noted that there was no statistically significant difference in time to infection onset in Hickman catheter and PICC. Despite the longer mean catheter days of Hickman catheters, there was no difference in the time infection developed.
There were some limitations in our study. First, this was a non-randomised retrospective study and selection bias existed. In an attempt to have a more focused and homogeneous group of patients, only oncology patients with a CVC were included, not haemodialysis or intensive care patients. We performed subgroup analysis of haematological and non-haematological malignancy. Some clinicians may have preferred a certain catheter, for example Hickman catheter, for longer duration of use and PICC for shorter duration. Thus we also performed subgroup analysis for catheters in place for >10 days and >30 days to eliminate the outlying effect of extra short-duration catheters. Second, although 6 years of data were analysed giving a total of 190 cases, there remained only a relatively small number of PICCs (29 cases, 15.3%) with only four infected. This limited further subgroup analysis. Studies of longer duration or prospective randomised control trials are warranted.
CONCLUSION
Vascular access is crucial to many oncology patients, but there is currently no consensus on the preferred CVC. In our 6-year study, we compared two widely used CVCs, the Hickman catheter and PICC. There was no statistically significant difference between the two in terms of CRBSI rate, time to infection onset, rate of infection per catheter day, non-infection complication rate, and overall complication rate. With the less invasive nature of PICC insertion, it offers a viable means of vascular access for oncology patients.
